Assessment of the pharmacodynamic properties of antimalarial drugs in vivo
about
Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deploymentAntimalarial drug resistanceClindamycin as an antimalarial drug: review of clinical trials.The evolution of tafenoquine--antimalarial for a new millennium?Therapeutic responses to different antimalarial drugs in vivax malariaEvolution of resistance to sulfadoxine-pyrimethamine in Plasmodium falciparumArtemisinin combination therapy for vivax malariaFosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malariaIntermittent presumptive treatment for malariaA randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand.Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient dataDiscovery and Current Status of Evaluation System of Bioavailability and Related Pharmaceutical Technologies for Traditional Chinese Medicines--Flos Lonicerae Japonicae--Fructus Forsythiae Herb Couples as an ExamplePharmacokinetic and pharmacodynamic considerations in antimalarial dose optimizationGametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient dataEndoperoxide antimalarials: development, structural diversity and pharmacodynamic aspects with reference to 1,2,4-trioxane-based structural scaffoldA comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malariaResidual antimalarials in malaria patients from Tanzania--implications on drug efficacy assessment and spread of parasite resistanceDuration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infantsA pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugsThe activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasitesP. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-actionA novel flow cytometric hemozoin detection assay for real-time sensitivity testing of Plasmodium falciparumImproving pharmacokinetic-pharmacodynamic modeling to investigate anti-infective chemotherapy with application to the current generation of antimalarial drugsEfficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studiesOptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimensEvidence of an increased incidence of day 3 parasitaemia in Suriname: an indicator of the emerging resistance of Plasmodium falciparum to artemetherGlobal research trends of World Health Organization's top eight emerging pathogens.Antimalaria action of antiretroviral drugs on Plasmodium berghei in miceStudy of the efficacy of antimalarial drugs delivered inside targeted immunoliposomal nanovectors.Real-time PCR for dihydrofolate reductase gene single-nucleotide polymorphisms in Plasmodium vivax isolatesTherapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations.Rectal artemisinins for malaria: a review of efficacy and safety from individual patient data in clinical studies.Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis.Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, GhanaModelling the epidemiological impact of intermittent preventive treatment against malaria in infants.Host control of malaria infections: constraints on immune and erythropoeitic response kineticsRevisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria.Immunity as a predictor of anti-malarial treatment failure: a systematic reviewIn-Vivo Efficacy of Chloroquine to Clear Asymptomatic Infections in Mozambican Adults: A Randomized, Placebo-controlled Trial with Implications for Elimination StrategiesRandomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria.
P2860
Q21090072-F91AD0B8-7D61-45F8-AEAE-25A0A847F3DDQ22061790-F2186E0B-8ABE-442D-BB79-96858FEAE203Q24536057-E9BB6E9E-8666-415B-A4C4-9D69B9242529Q24536171-5749A7FD-44E8-4017-ADE3-9383CB94B6FCQ24550626-B3584412-290A-4230-9896-CA292D65C75DQ24563685-B70485C8-B4C1-45B6-96B8-5A80A02FBC6BQ24622539-966912B2-70C8-4C31-BAE6-2F2AC4ADFBA1Q24680404-1F087B60-F5B2-491C-BBCC-8204796986EDQ24809091-66B49F86-F769-4E36-8A69-D2A690AE7725Q24814579-895B08B1-82B6-4131-A00E-F572072559D7Q26783902-F85647B1-6F99-41AB-89DC-912AC17F3019Q26824285-71363DBE-1D39-4893-8F57-2A84583E7ECAQ26830528-7D8B36D1-2A67-4C14-8FC3-F0B106432CFAQ28068072-7E4CA008-CE65-473C-AABA-0511A1D9E2BBQ28077102-2D60563E-953D-4E11-912C-5168E6468270Q28365926-B3A6AA8D-9280-44B1-BE1D-F3C0B4960BE1Q28472222-D8A06BD1-352C-42E6-BCCB-7610D8ABFA96Q28473083-BF63FE05-14DC-46E1-BDF5-E11B297C9B84Q28476638-94E2AC18-AB44-4186-A8D7-1E72CD103CB6Q28480979-B253D381-161C-485E-AF74-A1FA9DB1CE67Q28481199-6CE3E4A0-D5A6-400D-AB22-874DF9D6D5FEQ28486811-F19B30BF-38BF-4D1D-93B5-AEFBEFE30ADFQ28534701-A93893F3-F160-4A53-BFF4-28FAF75B3AEEQ28535686-DA0F1563-1CC2-47AB-AF1F-70C0BCC55811Q28831110-F8CC3E24-F270-43EE-A567-7080D0B112AFQ29353565-6E39C41C-EF88-437D-82A7-8C3C2043CD01Q30151375-8F9DB166-ED4B-4EF2-AB60-1CC01CC16D2CQ30424362-1F4E91E7-6CCB-4E9F-BB31-D16477BA8D6EQ30470222-184C6D15-E2A6-498E-883C-6774E5C5124DQ31081389-05913C97-19B5-4D4C-ACBA-6036A5DB0320Q31118886-E911BA85-E744-43A3-B2DD-13A5C23367C6Q31150958-7F0F61D2-1C08-4FAA-816C-3CFCAE3B76C8Q31153944-04FAF12A-2DA2-48D2-9A1B-FA782061372AQ33336570-450930D4-5013-4707-AA46-43C80AE31641Q33351939-776EFEEC-0B25-49C0-AB71-03404CAD14E6Q33363069-EB6CDB46-DD04-4616-BC66-706EF5ED0996Q33385477-2B1A800B-5DC0-4D5F-8D53-494BFE9DA4C3Q33582154-31E49933-0D25-4D4A-829D-F8D4B1EBFA4AQ33683683-E9EE2B1C-4A87-412C-9158-4DB3D8C91768Q33690621-ADF9D99A-4EE4-4FE9-88AA-F683F8B62115
P2860
Assessment of the pharmacodynamic properties of antimalarial drugs in vivo
description
1997 nî lūn-bûn
@nan
1997 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
name
Assessment of the pharmacodynamic properties of antimalarial drugs in vivo
@ast
Assessment of the pharmacodynamic properties of antimalarial drugs in vivo
@en
Assessment of the pharmacodynamic properties of antimalarial drugs in vivo
@nl
type
label
Assessment of the pharmacodynamic properties of antimalarial drugs in vivo
@ast
Assessment of the pharmacodynamic properties of antimalarial drugs in vivo
@en
Assessment of the pharmacodynamic properties of antimalarial drugs in vivo
@nl
prefLabel
Assessment of the pharmacodynamic properties of antimalarial drugs in vivo
@ast
Assessment of the pharmacodynamic properties of antimalarial drugs in vivo
@en
Assessment of the pharmacodynamic properties of antimalarial drugs in vivo
@nl
P2860
P921
P3181
P1476
Assessment of the pharmacodynamic properties of antimalarial drugs in vivo
@en
P2860
P304
P3181
P407
P577
1997-07-01T00:00:00Z